N'-[(2S,5S)-5-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5R)-4-[(2R,5S)-3-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5S)-4-aminooxy-3,5-dinitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4-nitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4,5-dinitroso-6-(nitrosomethyl)oxan-2-yl]oxy-6-[[(2S,5S)-3-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5R)-3,5-diaminooxy-4-nitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-5-nitroso-6-(nitrosomethyl)oxan-2-yl]oxymethyl]-3-hydroxy-5-nitrosooxan-2-yl]oxy-4-hydroxy-6-(nitrosomethyl)oxan-2-yl]oxy-2-methyl-4-nitroso-6-(nitrosomethyl)oxan-3-yl]acetohydrazide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N'-[(2S,5S)-5-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5R)-4-[(2R,5S)-3-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5S)-4-aminooxy-3,5-dinitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4-nitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4,5-dinitroso-6-(nitrosomethyl)oxan-2-yl]oxy-6-[[(2S,5S)-3-[(2S,5S)-3-(2-acetylhydrazinyl)-5-[(2S,5R)-3,5-diaminooxy-4-nitroso-6-(nitrosomethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-5-nitroso-6-(nitrosomethyl)oxan-2-yl]oxymethyl]-3-hydroxy-5-nitrosooxan-2-yl]oxy-4-hydroxy-6-(nitrosomethyl)oxan-2-yl]oxy-2-methyl-4-nitroso-6-(nitrosomethyl)oxan-3-yl]acetohydrazide
• 化学式: C₆₃H₉₇N₂₇O₄₅
• 分子量: 1952.6
• InChiKey: LJEUHMIQHMCOLJ-QKIKCRTLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -18
• 重原子数：
  135
• 可旋转键数：
  36
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  999
• 氢给体数：
  16
• 氢受体数：
  68

文献信息

• GLYCOSYLATED POLYPEPTIDE AND DRUG COMPOSITION CONTAINING SAID POLYPEPTIDE
  申请人：Glytech, Inc.

  公开号：EP2752424A1

  公开（公告）日：2014-07-09

  [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analogue thereof being replaced with a glycosylated amino acid.

  [问题]提供一种糖基化多肽，该多肽对体生长抑素受体具有亲和力，并且与体生长抑素相比，具有更好的血中稳定性。 [解决方案]糖基化多肽的特点是，体生长抑素或其类似物中的至少一个氨基酸被糖基化氨基酸取代。